Claims for Patent: 8,399,514

Summary for Patent: 8,399,514

Title:	Treatment for multiple sclerosis
Abstract:	Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
Inventor(s):	Lukashev; Matvey E. (Tewksbury, MA), O'Neill; Gilmore (Medford, MA)
Assignee:	Biogen Idec MA Inc. (Cambridge, MA)
Application Number:	13/372,426
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,399,514
Patent Claims:	1. A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject in need thereof a pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 mg per day. 2. The method of claim 1, wherein the pharmaceutical composition is administered in the form of a tablet, a suspension, or a capsule. 3. The method of claim 1, wherein the therapeutically effective amount is administered in separate administrations of 2, 3, 4, or 6 equal doses. 4. The method of claim 3, wherein the therapeutically effective amount is administered in separate administrations of 2 equal doses. 5. The method of claim 3, wherein the therapeutically effective amount is administered in separate administrations of 3 equal doses. 6. The method of claim 1, wherein the pharmaceutical composition consists essentially of dimethyl fumarate and one or more pharmaceutically acceptable excipients. 7. The method of claim 1, wherein the pharmaceutical composition consists essentially of monomethyl fumarate and one or more pharmaceutically acceptable excipients. 8. The method of claim 1, wherein the pharmaceutical composition is administered to the subject for at least 12 weeks. 9. The method of claim 6, wherein the therapeutically effective amount is administered to the subject in 2 equal doses. 10. The method of claim 9, wherein the therapeutically effective amount is administered to the subject for at least 12 weeks. 11. A method of treating a subject in need of treatment for multiple sclerosis consisting essentially of orally administering to the subject about 480 mg per day of dimethyl fumarate, monomethyl fumarate, or a combination thereof. 12. The method of claim 11, wherein about 480 mg of dimethyl fumarate per day is administered to the subject. 13. The method of claim 12, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses. 14. The method of claim 12, wherein the dimethyl fumarate is administered in separate administrations of 3 equal doses. 15. A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate is about 480 mg per day. 16. The method of claim 15, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses. 17. The method of claim 1, wherein the expression level of NQO1 in the subject is elevated after administering to the subject the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof. 18. The method of claim 11, wherein the expression level of NQO1 in the subject is elevated after administering to the subject about 480 mg per day of dimethyl fumarate, monomethyl fumarate, or a combination thereof. 19. The method of claim 15, wherein the expression level of NQO1 in the subject is elevated after administering to the subject the therapeutically effective amount of dimethyl fumarate. 20. A method of treating a subject in need of treatment for multiple sclerosis comprising treating the subject in need thereof with a therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 mg per day.